Fully Automated Clinical-Scale Separation of CD133 + Cells From Bone Marrow Aspirate

Abstract

than targeting either alone. Erythropoietin-producing hepatocellular carcinoma-A2 (EphA2)-specific CAR T cells were used to target the A549 tumor cells. EphA2-specific T cells when administered together with FAP-specific T cells, resulted in a significant decrease in tumor growth and increased survival compared to mice that received either EphA2-or FAPspecific T cells alone. Our study underscores the value of cotargeting both CAFs and cancer cells to increase the benefits of T-cell immunotherapy for solid tumors.

Intralesional Injection of Bone Marrow Aspirate Concentrate for the Treatment of Osteonecrosis of the Knee Secondary to Systemic Lupus Erythematosus: A Case Report

“…On the other hand, BM constitute a rich source of EPC (Hristov et al, 2003). EPCs can initiate neovascularization (Asahara et al, 1997(Asahara et al, , 1999Schatteman and Awad, 2004) and their intraoperative isolation at high yields from BMAC is feasible (Kolvenbach et al, 2010;Essl et al, 2013). In addition, BMAC promotes in vivo bone regeneration by bringing platelets and growth factors such as PDGF-BB and VEGF to the injury site (Hernigou et al, 2005;Holmes et al, 2007;Zhong et al, 2012;Gary et al, 2013).…”